Merck & Co., US58933Y1055

Merck & Co. stock: Baker to become lead director in January

Published on 11/19/2026 at 16:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Merck & Co. stock faces a board transition after Thomas Glocer set a May 2027 retirement. Douglas Baker will take over as independent lead director on January 1.

Board succession takes shape

  • Thomas H. Glocer plans to leave Merck's board at the annual shareholder meeting.
  • Douglas M. Baker brings governance and operating experience to the lead director role.
Merck & Co., US58933Y1055, Illustration mit AI erstellt.

Board succession takes shape

Merck said on November 18 that Thomas H. Glocer intends to retire from its board at the annual shareholder meeting in May 2027. The company also appointed Douglas M. Baker, Jr. as independent lead director, effective January 1, according to the Merck announcement.

Baker will succeed Glocer in the role. Merck said Baker has served on the board since 2022 and previously was chairman and chief executive officer of Ecolab. The announcement described the change as a planned governance transition.

What changes for investors

The transition changes the board's independent leadership while leaving the chief executive and chairman roles with Rob Davis. Glocer's retirement is scheduled for the shareholder meeting rather than taking effect immediately, so the next formal step is the company's annual meeting process.

Merck & Co. stock traded at 122.63 euros on Lang & Schwarz at 16:05 CET on Thursday, November 19, 2026.

Merck & Co. at a glance

  • Company: Merck & Co.
  • ISIN: US58933Y1055
  • Ticker: MRK
  • Trading venue: Lang & Schwarz
  • Price: 122.63 euros at 16:05 CET on November 19, 2026

For broader market developments, see Current market reports.

More news and analyses on Merck & Co. stock

Disclaimer...
en | US58933Y1055 | MERCK & CO. | boerse | 70536842 | bgmi